Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Kaufman, Jonathan L
[Clear All Filters]
2018
Mina R
,
Joseph NS
,
Kaufman JL
,
Gupta VA
,
Heffner LT
,
Hofmeister CC
,
Boise LH
,
Dhodapkar MV
,
Gleason C
,
Nooka AK
, et al.
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Cancer. 2018.
PubMed
Google Scholar
2019
Bailur JKini
,
McCachren SS
,
Doxie DB
,
Shrestha M
,
Pendleton KE
,
Nooka AK
,
Neparidze N
,
Parker TL
,
Bar N
,
Kaufman JL
, et al.
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
JCI Insight. 2019;5.
PubMed
Google Scholar
2020
Voorhees PM
,
Kaufman JL
,
Laubach JPeter
,
Sborov DWeston
,
Reeves B
,
Rodríguez C
,
Chari A
,
Silbermann R
,
Costa LJ
,
Anderson LD
, et al.
Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.
Blood. 2020.
PubMed
Google Scholar
2021
Josepht NS
,
Gupta VA
,
Wyman S
,
Graiser M
,
Kaufman JL
,
Almaula D
,
Andrews J
,
Hofmeister C
,
Dhodapkar M
,
Heffner LT
, et al.
Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life.
Transplant Cell Ther. 2021.
PubMed
Google Scholar
2022
Chhabra S
,
Callander N
,
Watts NL
,
Costa LJ
,
Thapa B
,
Kaufman JL
,
Laubach J
,
Sborov DW
,
Reeves B
,
Rodríguez C
, et al.
Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials.
Transplant Cell Ther. 2022.
PubMed
Google Scholar
2023
Voorhees PM
,
Sborov DW
,
Laubach J
,
Kaufman JL
,
Reeves B
,
Rodríguez C
,
Chari A
,
Silbermann R
,
Costa LJ
,
Anderson LD
, et al.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol. 2023.
PubMed
Google Scholar
Nooka AK
,
Kaufman JL
,
Rodríguez C
,
Jakubowiak A
,
Efebera Y
,
Reeves B
,
Wildes T
,
Holstein SA
,
Anderson LD
,
Badros A
, et al.
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol. 2023.
PubMed
Google Scholar